1. Introduction {#sec1}
===============

Visceral leishmaniasis (VL) is a vector-borne zoonotic disease responsible for one of the most neglected diseases linked to the poorest communities of low-income countries. The treatment of this disease is based on chemotherapy, since potential vaccines are in preclinical or early clinical stages of development ([@bib4]). Current pharmacopeia against this disease includes the first line antimony derivatives (Sb^V^), different formulations of the polyene fungicide amphotericin B (AMB) and the oral alkylphosphocholine miltefosine ([@bib2], [@bib33]). These compounds have many undesirable side effects that include Sb^V^ cardiotoxicity ([@bib44]), AMB nephrotoxicity ([@bib18]) and the developmental toxicity of miltefosine ([@bib8]). Therefore, the discovery and development of new drugs based on validated targets against VL is an urgent need, especially when Big Pharma companies have waived funds and efforts in research and development against this neglected disease.

Microtubule-targeting (antimitotic) drugs include compounds of diverse structure that can disrupt microtubule function by interacting with tubulin ([@bib19]). Microtubules are eukaryotic protein structures resulting from the polymerization of α/β-tubulin heterodimers. Microtubules are responsible for the formation of the mitotic spindle, cell shape, ciliary and flagellar motility and intracellular transport ([@bib22]). β-Tubulin is a GTP-hydrolyzing and highly conserved protein that interacts with α-tubulin, both conforming the basic structural subunit of microtubules. Microtubules of trypanosomatids have some unique features. They are constituted by the most abundant protein in these cells, since they are responsible for the subpellicular corset that conforms their specific shape ([@bib42], [@bib25]). In addition, they are relatively stable at low temperatures, in contrast to microtubules of many higher organisms, and they are also resistant to many drugs currently used in anthelminthic and anticancer therapies ([@bib48]). One of these drugs is colchicine, a potent inhibitor of tubulin polymerization in higher eukaryotes ([@bib47]). In mammals, colchicine binds to a β-tubulin domain located near the α/β-tubulin interface, where it prevents tubulin to adopt a straight linear structure required for further adequate polymerization ([@bib37]). Despite β-tubulin is highly conserved from trypanosomes to other higher eukaryotic organisms, up to eleven amino acid substitutions are found in the colchicine-binding site that may explain the resistance of these parasites to such drug ([@bib28]). These differences have been pointed as putative targets to be exploited in the design of new more selective polymerization inhibitors ([@bib24]).

Several drugs have been used to target trypanosomatids microtubules with low activity against mammalian counterparts. These drugs can act either by inhibiting or promoting tubulin polymerization. Dinitroaniline herbicides have shown activity against both *Leishmania* and *Trypanosoma* ([@bib14], [@bib15], [@bib16], [@bib17], [@bib46]), and tubulin has been implicated as being the target of these compounds ([@bib14], [@bib17], [@bib46]). One interesting natural compound in cancer chemotherapy is podophyllotoxin ([Fig. 1](#fig1){ref-type="fig"}), an antineoplastic and antiviral cytotoxic cyclolignan isolated from *Podophyllum* spp. (Berberidaceae) and several species of other genera and families. From a mechanistic point of view, it has been demonstrated that podophyllotoxin and most of its related 4′-methoxy congeners act by inhibiting tubulin polymerization through interaction at the colchicine-binding site ([@bib37]), while another not yet completely defined apoptosis mechanism has been proposed for some of those compounds included in other study ([@bib12]).Fig. 1Structures and numbering of positions and rings of podophyllotoxin (2a, left) and podophyllic aldehyde (14, right).Fig. 1

This article describes for the first time the evaluation of the killing effect of several series of semisynthetic podophyllotoxin derivatives on *Leishmania infantum*, the aetiological agent responsible for VL in humans and dogs in the Old World. For this purpose, an intracellular screening on macrophages isolated from naturally infected BALB/c mice with an infrared-emitting *L. infantum* strain was used. This method has the remarkable advantage of using host-infected cells under natural conditions, where splenocytes are still playing a role in the immunological response ([@bib38]). Furthermore, we have studied the potential role played by leishmanial tubulin as putative target of these compounds.

2. Material and methods {#sec2}
=======================

2.1. Chemistry {#sec2.1}
--------------

The chemical structures of the starting compounds podophyllotoxin and podophyllic aldehyde ([Fig. 1](#fig1){ref-type="fig"}) and the derivatives evaluated in this work are compiled in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}. Compounds were prepared according to previous reports ([@bib11], [@bib12], [@bib13], [@bib1]) and to unpublished procedures (chemical data not shown here). Their structures were respectively confirmed or assigned by either direct comparison with authentic samples, or through complete analysis of One- and Two-Dimensional ^1^H and ^13^C nuclear magnetic resonance (1D- and 2D-NMR, respectively), infrared (IR) and mass (MS) spectra for the new compounds.

2.2. Ethic statement {#sec2.2}
--------------------

The animal research described in this manuscript complies with Spanish Act (RD 53/2013) and European Union Legislation (2010/63/UE). The protocols used here were approved by the Animal Care Committee of the University of León (Spain), project license number (PI12/00104).

2.3. Promastigote cultures and *in vitro* assays {#sec2.3}
------------------------------------------------

*Leishmania infantum* BCN150 iRFP (henceforth referred as *L. infantum-iRFP*) is a genetically modified strain that constitutively incorporates the infrared *iRFP* encoding gen for infrared detection ([@bib9]) Promastigotes were cultured in M199 medium supplemented with 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 6.9, 10 mM glutamine, 7.6 mM hemin, 0.1 mM adenosine, 0.01 mM folic acid, 1 × RPMI 1640 vitamin mix (Sigma), 10% (v/v) heat-inactivated foetal calf serum (FCS; Fisher Scientific), and antibiotic cocktail (50 U/mL penicillin and 50 μg/mL streptomycin) and aliquoted into 96-well plates, 180 μL per well. Stock solutions of each compound were prepared in dimethylsulfoxide (DMSO) and stepwise diluted in M199 media (Sigma). Growing concentrations of each compound (0.07--300 μM) were added to wells. The final concentration of DMSO was never higher than 0.1%. 20 μL of each prepared concentration were added for well. DMSO and AMBdc were included as negative and positive controls, respectively. All compounds and controls were assayed by triplicate.

2.4. *Ex vivo* splenic explant cultures {#sec2.4}
---------------------------------------

To obtain primary infected splenic explants, BALB/c mice were inoculated intraperitoneally with 10^8^ *L. infantum-iRFP* metacyclic promastigotes. Briefly, infective promastigotes were isolated from stationary-phase culture by negative selection with peanut agglutinin (Sigma) ([@bib39]). Five weeks post-infection, mice were slaughtered and spleens were aseptically dissected, washed in cold phosphate-buffered saline (PBS), and placed in petri dishes. Small pieces were obtained by using a scalpel. In order to obtain a single-cell suspension, tissue was incubated with 5 mL of 2 mg/mL collagenase D (Roche) prepared in buffer (10 mM HEPES \[pH 7.4\], 150 mM NaCl, 5 mM KCl, 1 mM MgCl~2~ and 1.8 mM CaCl~2~) for 20 min. A cell suspension containing traces of spleen mass was gently passed through a 100-μm cell strainer to remove tissue fragments ([@bib3]). Splenocytes were washed twice with PBS by centrifugation (500 × *g* for 7 min at 4 °C) and resuspended in RPMI medium supplemented with 10% FCS, 1 mM sodium pyruvate, 1 × RPMI vitamins, 10 mM HEPES, and 50 U/mL penicillin and 50 μg/mL streptomycin at 37 °C under a 5% CO~2~ atmosphere. Cells were counted and diluted at different cell densities. Cells were seeded until confluence, and different concentrations of the studied compounds were administered to the explants for 48 h. The viability of infecting amastigotes was assessed by recording the fluorescence emission of infected splenocytes at 708 nm in an Odyssey (Li-Cor) infrared imaging system.

2.5. Cytotoxicity assay and selectivity index (SI) determination {#sec2.5}
----------------------------------------------------------------

Cytotoxicity of each compound was assessed on uninfected *ex vivo* explants and on the human hepatocarcinoma cell HepG2 line (ATCC HB-8065). HepG2 cells were cultured in The Glutmax Dulbecco\'s Modified Eagle\'s Medium (DMEM, Gibco), supplemented with 10% (v/v) FCS, 100 μg/mL penicillin and 100 μg/mL streptomycin. Both strains were seeded in 96-well plates in the presence of different concentrations of the assayed compound for 48 h at 37 °C. Viability of the cultures was determined using the Alamar Blue staining method, according to manufacturer\'s recommendations (Invitrogen).

Selectivity Indexes (SI) for the compounds were determined as the ratio between the CC~50~ values for non-infected mouse splenocytes (SI~s~) or CC~50~ values for HepG2 (SI~h~) and the EC~50~ values for amastigotes in infected splenocytes.

2.6. Purification of leishmanial tubulin {#sec2.6}
----------------------------------------

*L. infantum* (wild type strain) tubulin was isolated according to ([@bib50]). Two-liter flasks of *L. infantum* promastigotes were grown up to a cell density of approximately 1 × 10^9^ cells/mL. Cells were harvested and washed twice in PBS and resuspended in 0.1 mM piperazine N, N'-bis(2-ethanesulfonic acid) (PIPES) buffer (pH 6.9), containing 1 mM glycol ether diamine tetraacetic acid (EGTA) and 1 mM MgCl~2~. The resulting suspensions were sonicated on ice (5 cycles 5 pulses of 30 s each), and then were centrifuged in a Beckman Optima XL using a 70.1 Ti rotor at 40 000 × *g* for 45 min at 4 °C. The protein suspension was loaded onto a DEAE Sepharose (fast flow) and eluted with the same buffer containing 0.3 M KCl/0.75 M l-glutamate. The purity of the leishmanial tubulin suspension was more than 90% and was analyzed by polyacrylamide gel electrophoresis in denaturing conditions (SDS-PAGE).

2.7. Tubulin polymerization assays {#sec2.7}
----------------------------------

Reactions of tubulin-assembly/depolymerization by drugs were carried out in 384-wells black microplates with optical bottom (Thermo) in a final volume of 40 μL. Each reaction contained 1.2 mg/mL freshly isolated *Leishmania* tubulin, 0.1 mM PIPES (pH 6.9), 1 mM EGTA and 1 mM MgCl~2~, final concentrations, without or with the assayed compounds or colchicine as reference. The compounds were added to the microplate maintained at 4 °C. The assembly reaction was initiated by adding 2 μL of 40 mM GTP (2 mM final concentration). Variation of the absorbance at 340 nm was recorded in a Synergy HT microplate reader up to 45 min at 37 °C. IC~50~ values are reported as the mean ± SD of at least three different experiments assayed by duplicate.

2.8. Molecular modelling and structural analysis {#sec2.8}
------------------------------------------------

The homology model of *L. infantum* β-tubulin (GenBank LinJ.08.1280) was generated using the crystallographic structure of the bovine protein (PDB 4O2B) as template ([@bib36]). An initial model was obtained with the SWISS-MODEL modelling server ([@bib41]) and the tools Modeller 9.13 ([@bib40], [@bib20], [@bib30]). Molecular figures were prepared using VMD ([@bib23]) and UCSF Chimera ([@bib35], [@bib51]). The validation of the final model was carried out with MEAN ([@bib5], [@bib6], [@bib7]) and PROCHECK programs ([@bib26]).

Molecular docking studies were carried out to identify the binding affinities between the inhibitors and tubulins. Docking calculations were performed using the AutoDock 4.2 software ([@bib34]). A grid box of 66 × 44 × 66 points with a grid spacing of 0.375 Å and centered at the amino acid in position 200 was used to calculate the atom types needed for the calculations. The best binding mode of each molecule was selected based on the lowest binding free energy and the largest cluster. Ligand interactions with tubulin models of *Bos taurus* and *Leishmania* sp. were made with MAESTRO 10.2 software (Schrödinger, LLC, New York) using a 4 Å distance cut-off ([http://platinhom.github.io/ManualHom/Schrödinger_2015_2\_docs/maestro_user_manual.pdf](http://platinhom.github.io/ManualHom/Schr%d6dinger_2015_2_docs/maestro_user_manual.pdf){#interref0010})

3. Results {#sec3}
==========

3.1. Activity of podophyllotoxin derivatives against *L. infantum* {#sec3.1}
------------------------------------------------------------------

A set of 53 compounds with varied substitution arrangements on the fused tetracyclic core of podophyllotoxin or the tricyclic core of podophyllic aldehyde ([Fig. 1](#fig1){ref-type="fig"}) were tested *in vitro* for their ability to kill both stages of *L. infantum.* Results from the antileishmanial tests revealed that some of these compounds killed both promastigotes and splenic amastigotes at low micromolar EC~50~ level. Values of antiparasitic activity obtained with podophyllotoxin derivatives were generally better on intracellular amastigotes than on free-living promastigotes ([Table 1](#tbl1){ref-type="table"}). However, this result could be due to the close values found for anti-amastigote activity of the compounds and their cytotoxicity for uninfected host macrophages.Table 1Structures and bioactivity results for podophyllotoxin derivatives. Antileishmanial effects (EC50 ± SD) on promastigotes and amastigote-infected splenocytes (amastigotes) of L. infantum. Cytotoxicity effects (CC50 ± SD) on murine splenocytes and human HepG2 hepatocytes. Inhibition effects (IC50 ± SD) on leishmanial tubulin polymerization.Table 1Comp.REC~50~ (μM)CC~50~ (μM)CC~50~ (μM)IC~50~ (μM)*L. infantum* promastigotes*L. infantum* amastigotesMurine SplenocytesSI~S~Human HepG2SI~h~*Leishmania* tubulin**1**H\>100\>10098.6 ± 3.1\<1.0\>100*un*7.9 ± 0.3**2a**![](fx3.gif)\>10013.4 ± 0.8\>100\>7.40.7 ± 0.00.1**0.3 ± 0.02b**![](fx4.gif)\>100\>100\>100\<1.030.6 ± 2.1\<0.32.7 ± 0.1**3**![](fx5.gif)\>100\>10060.6 ± 7.7\<0.610.3 ± 0.9\<0.14.0 ± 0.2**4**![](fx6.gif)23.2 ± 0.5\>1000.4 ± 0.0\<0.01\>100*un*3.5 ± 0.8**5a**![](fx7.gif)13.8 ± 0.215.6 ± 0.116.4 ± 1.71.1\>100\>6.41.1 ± 0.1**5b**![](fx8.gif)24.9 ± 0.4**6.7 ± 0.3**18.0 ± 1.82.7\>100\> **14.9**5.0 ± 0.3**6a**![](fx9.gif)\>100**7.4 ± 0.4**6.4 ± 0.80.933.1 ± 2.14.53.4 ± 0.3**6b**![](fx10.gif)14.5 ± 0.3**9.3 ± 0.4**1.7 ± 0.20.2\>100\> **10.8**4.1 ± 0.1**7**[a](#tbl1fna){ref-type="table-fn"}![](fx11.gif)10.4 ± 0.644.3 ± 3.26.8 ± 0.20.2\>100\>2.37.7 ± 0.6**8**![](fx12.gif)61.2 ± 7.8\>10055.5 ± 3.3\<0.676.0 ± 1.5\<0.88.0 ± 1.4**9**![](fx13.gif)\>10053.7 ± 5.257.1 ± 2.51.1\>100\>1.96.9 ± 0.5**10**![](fx14.gif)\>10046.3 ± 8.815.9 ± 0.10.3\>100\>2.24.4 ± 0.9**11**![](fx15.gif)\>10079.1 ± 5.338.0 ± 2.50.5\>100\>1.38.8 ± 4.5**12**![](fx16.gif)66.4 ± 6.8\>10011.4 ± 2.00.1\>100*un*3.4 ± 0.5**13**![](fx17.gif)\>100**5.9 ± 1.1**4.3 ± 0.60.7\>100\> **17.1**5.5 ± 0.0Miltefosine**5.9 ± 1.42.40 ± 0.2**64.7 ± 7.0**26.9**50.4 ± 4.3**21***nt*AMBdc0.8 ± 0.10.3 ± 0.0\>20\>62.5*ntunnt*[^1]

We examined the EC~50~ values found for podophyllotoxins with antileishmanial effect against amastigotes in the context of molecular structure-activity correlation. An initial comparison revealed that while the unsubstituted core molecule deoxypodophyllotoxin (**1**) was essentially inactive (EC~50~ \> 100 μM), the presence of a single hydroxyl (OH) substituent at C-7α in podophyllotoxin (**2a**) conferred a significant antileishmanial activity (EC~50~: 13.4 μM). Similarly, the presence of small aliphatic alkyl or alkenyl substituents at position C-7 (compounds **4**--**6b**), did increase substantially the killing potency of the parental compound **1** on both *Leishmania* and mouse cells, while lesser or minimum enhancements were observed after the introduction of larger alkenyl (**7**, **8**), or hydroxyalkyl (**9**, **10**), or alkoxy/cycloalkoxy (**11**, **12**) substituents. Very interestingly, the presence of a 7α−pyranylglycol fragment in compound **13**, led to the most potent antiamastigote molecule of this series. Though the antileishmanial potency of several compounds of this series resulted in the range of the clinically used antimonial drugs and miltefosine ([@bib43], [@bib29]), none of the compounds assayed attained the leishmanicidal potency of AMBdc (EC~50~: 0.3 μM), which is currently the most potent reference drug in these assays.

To provide a uniform basis for comparison in these studies, we assayed all the compounds listed in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"} against mouse spleen macrophages --a primary non-tumoral culture, that represents the benchmark for comparative screening of antileishmanial drug candidates-- and on HepG2 hepatocytes, a human model for studies of liver drug toxicity. Although most compounds were less toxic for human hepatocytes, only two out from those 16 tested were fairly more potent against *Leishmania* amastigotes than cytotoxic for uninfected splenocytes. The highest selectivity indexes (SI~s~) for amastigotes were found for podophyllotoxin (**2a**, SI~s~ \> 7.4) and the isobutyl derivative **5b**, which displayed a modest SI~s~ = 2.7. The remaining compounds had SI~s~ ≤ 1.1 (similarly toxicity for both cell lines or even more toxic for the host cell) and therefore, they were not considered as candidates for further experiments.Table 2Structures and bioactivity results for podophyllic aldehyde derivatives with changes at the C9'-side chain R. Antileishmanial effects (EC~50~ ± SD) on promastigotes and amastigote-infected splenocytes (amastigotes) of *L. infantum*. Cytotoxicity effects (CC~50~ ± SD) on murine splenocytes and human HepG2 hepatocytes. Inhibition effects (IC~50~ ± SD) on leishmanial tubulin polymerization.Table 2Comp.REC~50~ (μM)CC~50~ (μM)CC~50~ (μM)IC50 (μM)*L. infantum* promastigotes*L. infantum* amastigotesMurine SplenocytesSI~S~Human HepG2SI~h~*Leishmania* tubulin**14**![](fx19.gif)89.5 ± 4.3**9.3 ± 0.5**\>100\> **10.8**\>100\>**10.8**2.0 ± 0.3**15**![](fx20.gif)57.0 ± 4.229.8 ± 1.6\>100\>3.3\>100\>3.3**0.7 ± 0.016**![](fx21.gif)35.2 ± 7.5*nt*98.2 ± 10.2*unntun*1.7 ± 0.1**17**![](fx22.gif)25.7 ± 3.618.1 ± 0.146.8 ± 7.02.668.9 ± 6.03.87.0 ± 0.7**18**![](fx23.gif)64.8 ± 4.9**4.3 ± 0.1**\>100\> **23.4**10.4 ± 0.82.4**0.9 ± 0.119**![](fx24.gif)\>10056.3 ± 1.442.0 ± 1.90.773.5 ± 11.61.3\>20**20**![](fx25.gif)17.5 ± 0.920.9 ± 0.121.0 ± 2.31.045.5 ± 5.62.24.3 ± 0.4**21**![](fx26.gif)79.9 ± 5.751.9 ± 0.334.1 ± 3.50.718.5 ± 0.70.42.0 ± 0.0**22**![](fx27.gif)14.5 ± 1.110.2 ± 0.551.3 ± 3.05.089.9 ± 4.08.83.1 ± 0.2**23**![](fx28.gif)**9.3** ± **0.79.9 ± 0.5**\>100\> **10.0**\>100\>**10.00.8 ± 0.024**![](fx29.gif)94.8 ± 7.9\>100\>100*un*14.3 ± 1.2*un*\>20**25**[a](#tbl2fna){ref-type="table-fn"}![](fx30.gif)\>100\>100\>100*un*\>100*un*\>20**26**![](fx31.gif)\>100\>10080.1 ± 4.9\<0.8027.2 ± 2.20.27\>20Miltefosine**5.9 ± 1.42.4 ± 0.2**64.7 ± 7.0**26.9**50.4 ± 4.3**21***nt*AMBdc**0.8 ± 0.10.3 ± 0.0**\>20\> **62.5***ntunnt*[^2]Table 3Structures and bioactivity results for podophyllic aldehyde derivatives with modifications at position C-9. Antileishmanial effects (EC~50~ ± SD) on promastigotes and amastigote-infected splenocytes (amastigotes) of *L. infantum*. Cytotoxicity effects (CC~50~ ± SD) on murine splenocytes and human HepG2 hepatocytes. Inhibition (IC~50~ ± SD) of leishmanial tubulin polymerization.Table 3Comp.REC~50~ (μM)CC~50~ (μM)CC~50~ (μM)IC~50~ (μM)*L. infantum* promastigotes*L. infantum* amastigotesMurine SplenocytesSI~S~Human HepG2SI~h~*Leishmania* tubulin**27**![](fx33.gif)38.3 ± 3.731.7 ± 2.1\>100\>6.36.6 ± 0.40.212.1 ± 0.8**28**![](fx34.gif)24.5 ± 1.524.5 ± 1.5\>100\>4.1\>100\>4.12.9 ± 0.3**29**![](fx35.gif)61.3 ± 0.759.4 ± 0.8\>100\>1.7\>100\>1.7\>20**30**![](fx36.gif)19.9 ± 2.119.9 ± 2.1\>100\>5.1*ntun*5.6 ± 0.5**31**![](fx37.gif)**9.4 ± 0.79.4 ± 0.7**\>100\>10.11.1 ± 0.00.11.2 ± 0.1**32**![](fx38.gif)14.2 ± 1.853.4 ± 4.579.3 ± 7.91.5*ntun*\>20**33**![](fx39.gif)41.1 ± 2.470.5 ± 3.738.7 ± 1.50.5\>1001.44.3 ± 0.6**34**![](fx40.gif)94.5 ± 3.015.6 ± 0.8\>100\>6.41.5 ± 0.10.1**0.8 ± 0.035**![](fx41.gif)91.0 ± 2.067.4 ± 2.0\>100\>1.532.4 ± 0.60.51.6 ± 0.2**36**![](fx42.gif)51.6 ± 1.8**7.5 ± 0.5**58.1 ± 2.77.7*ntun*9.0 ± 0.8**37**![](fx43.gif)14.2 ± 2.125.3 ± 1.08.8 ± 0.50.3\>100\>3.97.5 ± 1.1**38**![](fx44.gif)\>100\>100\>100*un*\>100*un*\>20**39**![](fx45.gif)45.2 ± 2.824.3 ± 0.522.9 ± 0.90.987.3 ± 6.43.63.1 ± 0.2Miltefosine**5.9 ± 1.42.4 ± 0.2**64.7 ± 7.0**26.9**50.4 ± 4.3**21.0**ntAMBdc**0.8 ± 0.10.3 ± 0.0**\>20\> **62.5***ntunnt*[^3]Table 4Structures and bioactivity results for lignan-heterocycle hybrids with modifications at C-9. Antileishmanial effects (EC~50~ ± SD) on promastigotes and amastigote-infected splenocytes (amastigotes) of *L. infantum*. Cytotoxicity effects (CC~50~ ± SD) on murine splenocytes and human HepG2 hepatocytes. Inhibition (IC~50~ ± SD) of leishmanial tubulin polymerization.Table 4Comp.R~1~R~2~EC~50~ (μM)CC~50~ (μM)CC~50~ (μM)IC50 (μM)*L. infantum* promastigotes*L. infantum* amastigotesMurine SplenocytesSI~S~Human HepG2SI~h~*Leishmania* tubulin**40**![](fx47.gif)COOCH~3~19.4 ± 2.1**4.5 ± 0.1**\>100\> **22.2**8.8 ± 0.32.01.51 ± 0.0**41**![](fx48.gif)COOCH~3~16.3 ± 1.9**9.7 ± 1.8**86.2 ± 0.18.9*ntun*16.1 ± 2.1**42**![](fx49.gif)COOCH~3~13.9 ± 2.812.1 ± 0.4\>100\>8.446.8 ± 1.33.912.1 ± 1.2**43**![](fx50.gif)COOCH~3~\>10099.4 ± 6.315.6 ± 0.60.247.5 ± 0.30.5\>20**44**![](fx51.gif)COOCH~3~\>10042.3 ± 3.1\>100\>2.4\>100\>2.4\>20**45**![](fx52.gif)COOCH~2~CH~3~16.1 ± 2.2**2.5 ± 0.2**71.8 ± 6.0**29.0***ntun*\>20**46**![](fx53.gif)COOCH~3~34.3 ± 1.7**7.3 ± 0.2**\>100\> **13.7**51.2 ± 3.67.0**0.7 ± 0.047**![](fx54.gif)COOCH~3~\>100**2.2 ± 0.3**\>100\> **45.5**9.9 ± 0.64.4\>20**48**![](fx55.gif)COOCH~3~11.0 ± 0.7**8.9 ± 0.6**71.0 ± 1.58.065.9 ± 3.37.41.3 ± 0.0**49**![](fx56.gif)COOCH~3~47.0 ± 5.221.2 ± 1.140.7 ± 6.51.995.0 ± 14.04.5**0.3 ± 0.050**![](fx57.gif)COOCH~3~\>10043.4 ± 2.153.3 ± 3.51.292.5 ± 6.82.1\>20Miltefosine**5.9 ± 1.42.4 ± 0.2**64.7 ± 7.0**26.9**50.4 ± 4.3**21.0**ntAMBdc**0.8 ± 0.10.3 ± 0.0**\>20\> **62.5***ntunnt*[^4]

The glycolic podolignan **13,** though practically inactive against promastigotes and highly cytotoxic for mouse splenocytes, was the most potent molecule of this series against amastigotes, and also turned out to be the most selective with respect to human hepatocytes (SI~h~ \> 17.1). These facts suggest the potential interest of extending the antileishmanial evaluation to other podolignans containing such a glycolic fragment attached to the C-7 position.

3.2. Activity of podophyllic aldehyde derivatives against *L. infantum* {#sec3.2}
-----------------------------------------------------------------------

In a second instance, the antileishmanial activity of three series of compounds derived from podophyllic aldehyde (**14**) was evaluated. This aldehyde was considered as a potential antiparasitic lead compound, due to its selectivity previously shown against cancer *vs* normal cells ([@bib21]). The aldehyde **14** is a cyclolignan resulting from a multi-step chemical process around the fused γ-lactone ring of podophyllotoxin (including D-ring lactone rupture with C-8′ epimerization and C-9′ esterification, C7-C8 dehydration and C-9 oxidation), finally leading to the C9-aldehyde function and the β-axially-oriented carboxylic methyl ester at C-9'. Many compounds of the first series of podophyllic derivatives (**14**--**24**), retained the aldehyde function at C-9 in order to investigate the influence of nature and size of the ester chain at position C-9′ upon the antileishmanial activity and cytotoxicities ([Table 2](#tbl2){ref-type="table"}). Additionally, the series includes one compound with the common trimetoxyphenyl (Ar) fragment extended to a methoxyphthalazine moiety (**25**) and a pyrrolidide (**26**). These are representatives of two available sub-series of compounds, aiming to detect the respective and possible influence on the activity by enlarging the polycyclic structure, and by changing from the ester to an amide function at position C-9'.

As in the case of podophyllotoxin derivatives, though with the exceptions of the chloropurine derivative **20** and the pseudodimeric diester **24**, the antileishmanial potency of those active C9'-esters was generally higher (compds. **14, 15, 17--19, 21** and **22**) against the amastigote form of the parasite, or similar (**23**--**26**) against both forms. The virtual inactivity observed for the phthalazine **25** and the pyrrolidide **26** led to preclude further evaluation of their related sub-series of analogues.

Interestingly, related to the antiparasitic selectivity within this series ([Table 2](#tbl2){ref-type="table"}), the starting lead compound, the aldehyde **14**, and two of its more potent derivatives, the glycolate ester **18** and the cinnamyl ester **23,** displayed significant SI~s~ values of SI~s~ \> 10.8, \>23.4 and \> 10.0 respectively, although the derivative **18** showed higher cytotoxicity for HepG2 hepatocytes (SI~h~ = 2.4). On the contrary, the trimethoxybenzyl ester **22** provided low hepatocyte toxicity (CC~50~: 89.9 μM), but less significant SI~s~ values (SI~s~ = 5.0). In addition, the presence of a terminal olefin, the allyl ester **15** behaved in a similar way (SI~s~ \> 3.3). For other compounds of the series, the actual EC~50~ values were compromised with their respective CC~50~ and with splenocytes survival.

The second series of podophyllic aldehyde derivatives ([Table 3](#tbl3){ref-type="table"}), included those compounds resulting from the reaction of the aldehyde (-CHO) group at position C-9 with a number of amine, hydrazine and hydroxylamine reagents, thus leading to a diversity of compounds, including the saturated amine **27**, the hydrazone **28**, the oxime **29**, the monoimines **30--37**, the symmetric azine **38** and the di-imine **39**. The compounds were evaluated on both stages of *L. infantum* and, as expected ([Table 3](#tbl3){ref-type="table"}), the nature and size of the imine substituents influenced their leishmanicidal activity. It should be noted that compounds with the imino C9=N double bond may decompose during the assays and, consequently, would act as pro-drugs of the starting podophyllic aldehyde. This could particularly happen in the case of *in vivo* or prolonged *in vitro* assaying, due to their possible metabolic or chemical hydrolysis, with simultaneous liberation of the corresponding amine.

Unlike the majority of molecules so far tested, a moderate but significant SI~s~ was found for most of compounds belonging of this series. The most potent compounds of this group in killing *L. infantum* amastigotes were the thiazolyl-imine **36** (EC~50~ = 7.5 μM), and the phenolic-imine **31** (EC~50~ = 9.4 μM), which also displayed the highest SI~s~ values (7.7 and \> 10.1, respectively). The remaining compounds had lower potency and more modest selectivities. It should be also noted the potential hepatotoxicity of this series of compounds, with the trifluoroethylhydrazone **28**, as the only member showing a SI~h~ value higher than 4. However, some attention should be paid to the saturated amine **27** (SI~s~ \> 6.3), because despite its discrete leishmanicidal potency (EC~50~ = 31.7 μM) and its certain hepatoxicity (SI~h~ = 0.2), it was unable to destroy murine splenocytes at the maximum concentration tested of 100 μM. This would be chemically supported by the less reactive character of amines with respect to the unsaturated imines, oximes and hydrazones. This would suggest to extend the leishmanicidal and cytotoxicity evaluations to other saturated analogues, with other secondary or tertiary amine functions attached to C-9. Furthermore, from the chemical and pharmacological mechanistic points of view, the amines would act by themselves rather than as pro-drugs, as they are more stable than those unsaturated derivatives and should need a harder metabolic processing of oxidative deamination to liberate the precursor podophyllic aldehyde **14**.

Finally, [Table 4](#tbl4){ref-type="table"} shows the structures and antileishmanial results of the third series of podophyllic aldehyde derivatives **40--50**. All these compounds contain a bicyclic heterocyclic system built on the aldehyde function and integrating the C-9 carbon atom of the lignan into the heterocyclic fragment. The added fragments were structurally close to nucleic purine bases, benzoxazole, benzimidazole and benzothiazole systems, which are fragments often present in many antiparasitic and antimicrobial agents. In general, as in the above series, these hybrid compounds were more effective in killing intracellular amastigotes than against promastigotes of *L. infantum*. Interestingly, more than the half of the tested compounds of this series had EC~50~ values below 20 μM, being the benzimidazole derivatives **45** (EC~50~ = 2.5 μM) and **47** (EC~50~ = 2.2 μM) that presented the highest and similar antileishmanial potencies. The cytotoxicity of these compounds, was also assayed on murine splenocytes. Most interestingly, these lignan-benzimidazole/benzoxazole hybrids were revealed as very selective against amastigote-infected splenocytes, with high values for the lignan-benzimidazole hybrids **47** (SI~s~ \> 45.5), **45** (SI~s~ = 29.0) and **46** (SI~s~ = \> 13.7), and significant values for the lignan-benzoxazole hybrids **40** (SI~s~ \> 22.2), **41** (SI~s~ = 8.9), **42** (SI~s~ \> 8.4) and the dichlorobenzimidazole **48** (SI~s~ = 8.0). Unfortunately, cytotoxicities for human HepG2 hepatocytes were not so good and only the compounds **46** and **48** displayed good SI~h~ values of 7.0 and 7.4, respectively.

3.3. Inhibition of tubulin polymerization {#sec3.3}
-----------------------------------------

The entire list of compounds was assayed on freshly purified tubulin obtained from *L. infantum* promastigotes as described above (see [Fig. S1 A and B from Supplementary Material](#appsec1){ref-type="sec"}). Firstly, the compounds were tested at a single concentration of 20 μM to discard less potent substances. Then, those active inhibitors of tubulin polymerization were tested at different concentrations to determine their IC~50~ values (results shown in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}). Podophyllotoxin (**2a**) and podophyllic aldehyde (**14**) were used for comparison purposes within their respective series 1 and 2--4. Vinblastine, that inhibits completely tubulin polymerization at 25 μM concentration, was used as positive control in the assay.

As expected, a relevant number of compounds, including podophyllotoxin (**2a**) and six podophyllic aldehyde derivatives (**15, 18, 23, 34, 46** and **49**) showed IC~50~ values under the μM level, while other 20 compounds ranged between 1 and 5 μM. The most effective inhibitors of Leishmania tubulin polymerization were the lignan-imidazopyridine hybrid **49** (IC~50~ = 310 nM) and the lignan-benzimidazole hybrid **46** (IC~50~ = 660 nM), both in the range of potency of podophyllotoxin (**2a,** IC~50~ = 320 nM) and fairly more potent than podophyllic aldehyde (**14**, IC~50~ = 2.0 μM) (see [Fig. S2](#appsec1){ref-type="sec"} from Supplementary Material). Surprisingly, the antileishmanial and the antitubulin results did not fully correlate. The most potent anti-tubulin, the imidazopyridine hybrid **49**, had resulted less potent (EC~50~: 21.2 μM) and fairly less selective (SI~s~: 1.9) antileishmanial than the above-mentioned benzimidazole (SI~s~: 8.0--45.5) and benzoxazole (SI~s~: \> 8.4--22.2) hybrids.

3.4. Molecular modelling {#sec3.4}
------------------------

The colchicine-binding site lies at the interface between the α and β subunits of the tubulin heterodimer ([Fig. 2](#fig2){ref-type="fig"}A and B). Three interaction zones in the β subunit (zones 1, 2 and 3) have been identified in the mammalian model ([@bib31]). Both colchicine and podophyllotoxin interact with amino acids of the α subunit and with those near the interface of zone 2 in the β heterodimer. Amino acids involved in the interaction with colchicine in the α subunit are fully conserved without any remarkable polymorphism in *Leishmania*. However, several non-synonymous mutations of *Leishmania* β tubulin may be responsible for the lack of activity of colchicine in trypanosomatids. Amongst them, ^259^Met → ^259^Leu; ^316^Ala → ^316^Ser and ^354^Ala → ^354^Ser ([Fig. 2](#fig2){ref-type="fig"}C) are involved in the interaction with the trimethoxybenzene fragment of colchicine, and would be responsible for its difficult conformational arrangement into the binding site. These and other site changes are responsible for the constrained volume of colchicine binding site in leishmanial tubulin (from 726.6 Å^3^ in mammals to 696.0 Å^3^ in *Leishmania*), and should explain why colchicine is unable to interact favorably with its own leishmanial binding site ([Fig. 2](#fig2){ref-type="fig"}D and E).Fig. 2(A) Ribbon 3D diagram of α and β subunits of *L. infantum* tubulin dimer. The homology model was generated by superimposition of the structure generated with the α/β-tubulins from *L. infantum* (GenBank LinJ.13.0330 and LinJ.08.1280) using the crystallographic structure of the bovine protein with colchicine (PDB:4O2B) as template \[30\]. (B) Structural motifs of calf α/β tubulin involved in colchicine binding site. Colchicine (violet) is bound to domains and secondary structure elements of both subunits. In the α-tubulin, amino acids associated with the T5 loop form part of the pocket-binding site. Elements of β-tubulin are presented and defined as follows: α-helices H7-8, β sheets 8--9 and T7 loop. (C) Multiple alignment of the peptide sequence of the β subunit of tubulin *B. taurus*, *Saccharomyces cerevisiae*, *L. infantum* and *Trypanosoma brucei* involved in the colchicine binding site, showing the pointed polymorphisms in yellow. Representation of a tubulin dimer with the colchicine binding pocket surface in *B. taurus* (D) and *L. infantum* (E). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2

A modelling study of the β subunit of *Leishmania* tubulin was conducted on the basis of an interaction complex model of calf tubulin with podophyllotoxin (PDB:4O2B) \[30\]. For this purpose, the co-crystal model of calf tubulin-colchicine complex was used as template for *Leishmania* tubulin modelling, using the AutoDockTools program. Interactions between podophyllotoxin analogues with calf and *Leishmania* tubulins were calculated with AUTODOCK. Apparently, most of the compounds bind tightly to *Leishmania* tubulin ([Table 5](#tbl5){ref-type="table"}), although some compounds interact with calf tubulin with higher affinity than with *Leishmania* tubulin. This may be due to the actual conformations adopted by different podolignans in their respective interactions with calf or leishmanial β-tubulins.Table 5Tubulin polymerization inhibition, docking energy values and correlative data for representative lignans and hybrid compounds of this research.Table 5Compd.*Leishmania* tubulin polymerization inhibition (IC~50~ μM)Docking energy *Leishmania* (kcal/mol)Docking energy *Bos taurus* (kcal/mol)**2a**0.32 ± 0.03−9.0−8.0**5a**1.14 ± 0.14−8.9−7.7**14**2.05 ± 0.32−7.5−7.4**15**0.75 ± 0.04−7.9−7.9**21**2.02 ± 0.02−7.4−7.4**23**9.92 ± 0.55−10.2−7.9**31**1.16 ± 0.06−8.4−8.8**34**0.78 ± 0.04−7.8−9.1**35**1.64 ± 0.18−8.5−8.4**40**1.51 ± 0,05−8.3−8.3**46**0.66 ± 0.01−8.4−10.3**48**1.32 ± 0,01−9.8−7.1**49**0.31 ± 0.01−9.2−10.3**Colchicine**\>100*df*−10.3[^5]

To analyze such conformational differences in the interaction complexes, podophyllotoxin (**2a**), podophyllic aldehyde (**14**) and two derivatives with strong antitubulin effect (**46** and **49**) were submitted to a conformational force field optimization implemented by ChemDraw 3D, and docked into leishmanial and calf tubulins. [Fig. 3](#fig3){ref-type="fig"} (left columns) shows that the docking of podolignans within the pocket-binding site of *Leishmania* tubulin can be different enough (**2a**, **46**, **49**) from those found in mammal tubulin (right column), while other (**14**) results close similar.Fig. 3Calculated docking of podophyllotoxin (2a), podophyllic aldehyde (14) and the lignan-heterocycle hybrids (46) and (49), as representative bioactive compounds of this research, in the colchicine site of *L. infantum* (left panels) and *Bos taurus* tubulins (right panels). The program used for calculating the figure was AutoDock 4.2 software.Fig. 3

The key interactions between the selected compounds and their corresponding amino acids in the colchicine-site of *Leishmania* and calf tubulins are described in the 2D interaction maps included in [Fig. 4](#fig4){ref-type="fig"} (See also other 2D maps in [Fig. S3, of supplementary material](#appsec1){ref-type="sec"}). Most amino acids involved in the interaction of podophyllotoxin with β-tubulin in calf are conserved in the *Leishmania* model. However, several changes alter the conformational disposition of the drug within the pocket-binding site of the parasite protein. Looking at 2D maps of podophyllotoxin (**2a**), the change of ^259^Met → ^259^Leu in the zone 1 ([Fig. 3](#fig3){ref-type="fig"}C) of *Leishmania* β-tubulin alters deeply the disposition of the tetracyclic core of podophyllotoxin in *Leishmania*. The dioxole ring of **2a**, surrounded by the amino acids ^258^Asn in zone 1 and ^314^Thr and ^315^Val of zone 2 in calf tubulin, is exposed to solvent in the *Leishmania* model due to a 180° rotation of the molecule. However, the trimethoxyphenyl group is not exposed to solvent in this model due to the ^250^Ala→^250^ Ser change in zone 1 and ^316^Ala→^316^Ser change in zone 2. These changes can also explain the improved interaction of podophyllotoxin with *Leishmania* β-tubulin in terms of a better docking energy (−9.0 kcal/mol in leishmanial *vs* −8.0 kcal/mol in mammalian tubulins; [Table 5](#tbl5){ref-type="table"}). Looking at the interaction complexes ([Fig. 3](#fig3){ref-type="fig"}), 2D maps ([Fig. 4](#fig4){ref-type="fig"}) and docking energies ([Table 5](#tbl5){ref-type="table"}) of the hybrid compounds **46** and **49**, more important conformational and docking energy differences can be observed. Obviously, such differences are due to the bicyclic heterocyclic fragments attached to the lignan and their bulkier structures, in comparison with those in **2a** and **14**. Similar studies have been carried out with other compounds included in [Table 5](#tbl5){ref-type="table"} and graphic results and data can be found in supplementary files ([Fig.S3 and Table S1](#appsec1){ref-type="sec"}).Fig. 42D protein ligand interaction maps for compounds 2a (podophyllotoxin), 14 (podophyllic aldehyde), 46 (lignan-benzimidazole hybrid) and 49 (lignan-imidazopyridine hybrid) on *Leishmania* (left) and *Bos taurus* (right) tubulins. Amino acids at a distance lesser than 4 Å are marked as follows: cationic (purple), anionic (red), hydrophobic (green), polar (blue), and parts exposed to solvent (grey). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 4

4. Discussion {#sec4}
=============

Despite the phylogenetic conservation of α- and β-tubulins, subtle structural differences in the tubulin-binding site for certain antitubulin compounds in kinetoplastids have suggested these proteins as a potential druggable target. Specifically, colchicine is a potent antimitotic drug that has given rise to lots of new compounds, including podophyllotoxin derivatives and combretastatin A4 analogues, some of them under clinical trials ([@bib24]). From the comparison of 3D models of calf and *Leishmania* β−tubulins, the colchicine-binding site of the β-heterodimer is specially enriched in amino acid polymorphisms, which reduce the volume of this binding site in *L. infantum* ([Fig. 2](#fig2){ref-type="fig"}D and E). In addition to the constrained volume, another reason to explain the lack of effect of colchicine can be found in the modification of hydrophobicity in the binding site. From the 3D model shown in [Fig. 2](#fig2){ref-type="fig"}B (and embedded table) the colchicine-binding site lies between the α and β subunits. It consists of two S8 and S9 sheets, two H7 and H8 helices connected by the T7 hinge, and the T5 loop at the α-tubulin subunit. H7 helix contains the ^241^Cys, which interacts with the conformationally restricted trimethoxybenzene moiety present in colchicine and with the more flexible trimethoxyphenyl group of podophyllotoxin derivatives. According to this model it can be suggested that the substitution of ^259^Met from zone 1 (comprised by T7 loop and H8 helix) of calf β-tubulin by a^259^Leu may contribute to the significant displacement of planar R1 pharmacophore (A to D rings) of podophyllotoxin within the Leishmanial binding pocket. To this spatial change, the existence of three non-synonymous mutations within zones 1, 2 and 3 (^250^Ala→^250^Ser, ^316^Ala→^316^Ser and ^354^Ala→^354^Ser) can generate some hydrophobicity reductions in several parts of the *Leishmania* binding pocket. Many of those amino acids that have been changed should be involved in van der Waals (Ala)/polar (Ser) interactions with the conformationally rigid colchicine molecule, and also with combretastatins and podophyllotoxins, through their at least partially rotatable trimethoxyphenyl ring ([@bib45]).

In other sense, the analysis of the effects of podophyllotoxin derivatives has shown that the hydroxyl group at position C-7α was essentially needed for the antileishmanial effect. Lack or change of the substituent at such position and orientation, represented by deoxypodophyllotoxin (**1**), the 7-epimer epipodophyllotoxin (**2b**) and the keto derivative podophyllotoxone (**3**), led to ineffective killers of *Leishmania* parasites with much lower effects in preventing tubulin polymerization ([@bib27]).

Here, we also found that there was no improvement in the polymerization inhibition of leishmanial tubulin with compounds having other substituents at positions C-7α or C-7β. This decrease in activity was previously observed on other cell lines, ([@bib10], [@bib27], [@bib1]), and could be due to additional spatial hindering for the binding to tubulin. However, relevant exceptions of highly potent polymerization inhibition of mammalian tubulin were demonstrated for some 7α-alkyl and 7α-hydroxycycloalkyl derivatives, as for 7α-isopropyl derivative **4** and for the glycolic pyranyl derivative **13** ([@bib1]) included in this research ([Table 1](#tbl1){ref-type="table"}).

It was also demonstrated that many podophyllic aldehyde derivatives had interesting antileishmanial activity, with SI values higher than those provided by podophyllotoxin. Modelling of podophyllic aldehyde (**14**, [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}) shows a pattern of interaction similar to podophyllotoxin at the colchicine site of leishmanial tubulin. In this case, the ε-amino group of ^254^Lys ([Fig. 4](#fig4){ref-type="fig"}/**14**) in zone 1 of *L. infantum* β-tubulin is close enough to interact with the C9-carbonyl group of podophyllic aldehyde, while ^247^Gln may interact with the dioxolic ring A. On the other hand, the trimethoxyphenyl fragment would undergo some interaction disturbances due to the presence of ^250^Ser, ^316^Ser and ^318^Leu in *Leishmania* tubulin, with respect to those of ^250^Ala, ^316^Ala and ^318^Ile in bovine tubulin.

For the series of compounds with the C9-aldehyde group integrated into a bicyclic heterostructure and the β-carboxyester function at C-9', we observed that some of them displayed more potent antileishmanial effects, also with good SI values for infected splenocytes. In general, these hybrid compounds showed better results in terms of potency than those from the other series, and can be compared well with those for glucantime and miltefosine ([@bib43], [@bib29]), although they were less effective than AMBdc. Concerning the inhibitory action on leishmanial tubulin, the hybrid benzoxazole **40**, the benzimidazoles **46** and **48** and the imidazopyridine **49** inhibited its polymerization at low μM levels or even below micromolar concentrations. The benzoxazole **40** had a strong antitubulin effect (IC~50~; 1.51 μM) in parallel with its high antileishmanial potency and selectivity (SI~s~ \> 22.2). However, the dimethylbenzimidazole **47**, which displayed a higher antileishmanial potency and the highest selectivity (SI~s~ \> 45.5) of all the compounds tested, did not show good inhibitory activity (IC~50~ \> 20 μM) on tubulin polymerization. It is worth mentioning here that benzimidazole and benzothiazole compounds are well-known inhibitors of tubulin polymerization in nematodes. Several efforts to find correlations between antileishmanial and/or antitubulin effects with docking energies for the compounds included in [Table 5](#tbl5){ref-type="table"} were unsuccessful. These facts suggest the probable existence of an alternative mechanism of action for a number of compounds that need to be studied and established through further research.

5. Conclusions {#sec5}
==============

In summary, we have evaluated and analyzed the antileishmanial effects of 53 podophyllotoxin and podophyllic aldehyde derivatives on both promastigotes and splenocytes naturally infected with amastigotes of *L. infantum*. Several discrepancies found between antileishmanial and antitubulin results displayed by compounds with different but close structures, suggest the existence of another mechanism of action, alternative or complementary to the inhibition of tubulin polymerization as responsible for the antileishmanial effects. This evidence merits further studies to confirm it and explain how these compounds are acting on a different therapeutic target, also aiming to progress in the development of new and better drugs against this deadly and still neglected disease.

Conflict of interest {#sec6}
====================

There are none.

Appendix A. Supplementary data {#appsec1}
==============================

The following is the supplementary data related to this article:Online dataOnline data

This collaborative research was carried out under the auspices of the RICET-ISCIII Network (Groups: RD12/0018/0002, RD16/0027/0008 and RD06/0021/1004) and the CYTED Program (214RT0482). It was supported by Ministerio de Economía y Competitividad (MINECO; AGL 2010-16078/GAN; CTQ 2015-68175-R), co-financed by Fondo Social Europeo, Instituto de Salud Carlos III-Feder (PI12/00104) and Junta de Castilla y León (Grants to: Gr208, SA221U13 and Gr238, LE182U13).

Supplementary data related to this article can be found at [http://dx.doi.org/10.1016/j.ijpddr.2017.06.003](10.1016/j.ijpddr.2017.06.003){#intref0015}.

[^1]: ∼1:1 mixture of C-7α and C-7β epimers. SI~S~: Selectivity Index (mouse splenocytes); SI~h~: Selectivity Index (human HepG2); *nt*: not tested; *un*: undefined. Significant values (EC~50~: \<10 μM, SI: \> 10, and IC~50~: \<1 μM) are **bolded** for comparison purposes.

[^2]: Complete structure of this compound. SI~s~: Selectivity Index (splenocytes); SI~h~: Selectivity Index (HepG2); *nt*: not tested; *un*: undefined. Significant values (EC~50~: ≤10 μM, SI: ≥ 10, and IC~50~: ≤ 1 μM) are **bolded** for comparison purposes.

[^3]: SIS: Selectivity Index (splenocytes), SIh: Selectivity Index (HepG2), *nt*: not tested, *un*: undefined. Significant values (EC50: \<10 μM, SI: \> 10, and IC50: \<1 μM) are **bolded** for comparison purposes.

[^4]: SI~S~: Selectivity Index (splenocytes), SI~h~: Selectivity Index (HepG2), *nt*: not tested, *un*: undefined, Significant values (EC~50~: \<10 μM, SI: \> 10, and IC~50~: \<1 μM) are **bolded** for comparison purposes.

[^5]: *df:* docking failure.
